Literature DB >> 8829301

Antiemetic support: a continuous challenge.

M Dicato.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8829301     DOI： 10.1007/bf01358876

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  5 in total

Review 1.  Comparative studies of various antiemetic regimens.

Authors:  F Roila; M Tonato; E Ballatori; A Del Favero
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

2.  Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam.

Authors:  D Cunningham; M Dicato; J Verweij; R Crombez; P de Mulder; A du Bois; A Stewart; J Smyth; P Selby; D van Straelen; R Parideans; B McQuade; J McRae
Journal:  Ann Oncol       Date:  1996-03       Impact factor: 32.976

3.  Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy.

Authors:  R R Silva; R Bascioni; F Giorgi; L Acito; L Giustini; G De Signoribus; M Marcellini; E T Menichetti; L Giuliodori
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

Review 4.  Methodology of trials with antiemetics.

Authors:  M Tonato; F Roila; A Del Favero; E Ballatori
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

5.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.